The Challenge Of Cmc Regulatory Compliance
nnovation, including cell and gene therapies, biosimilars, and novel antibody formats, adds layers of complexity to CMC compliance. Emerging modalities often lack established regulatory precedents, forcing companies to engage in iterative
